<code id='BD8DF5A860'></code><style id='BD8DF5A860'></style>
    • <acronym id='BD8DF5A860'></acronym>
      <center id='BD8DF5A860'><center id='BD8DF5A860'><tfoot id='BD8DF5A860'></tfoot></center><abbr id='BD8DF5A860'><dir id='BD8DF5A860'><tfoot id='BD8DF5A860'></tfoot><noframes id='BD8DF5A860'>

    • <optgroup id='BD8DF5A860'><strike id='BD8DF5A860'><sup id='BD8DF5A860'></sup></strike><code id='BD8DF5A860'></code></optgroup>
        1. <b id='BD8DF5A860'><label id='BD8DF5A860'><select id='BD8DF5A860'><dt id='BD8DF5A860'><span id='BD8DF5A860'></span></dt></select></label></b><u id='BD8DF5A860'></u>
          <i id='BD8DF5A860'><strike id='BD8DF5A860'><tt id='BD8DF5A860'><pre id='BD8DF5A860'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:68
          Two researchers look at a computer monitor showing a graph and other data
          Adobe

          Research universities are voicing concerns over some proposed changes to the process for reviewing scientific misconduct allegations, citing worries that new government requirements would hobble their own independent procedures and constitute a huge administrative burden.

          Nearly two decades since it last released research misconduct rules, the U.S. Office of Research Integrity (ORI) is ready to update its requirements for ensuring the scientific standards of projects funded by the U.S. Department of Health and Human Services, including the National Institutes of Health.

          advertisement

          The proposed changes, published on Oct. 6, include a new formal process that institutions would follow in reviewing allegations, a 30-day deadline for institutions to assess allegations, and provisions that make it harder to quickly dismiss cases that institutions believe to be “honest errors.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          Sage hopes for a blockbuster in antidepressant now before FDA
          Sage hopes for a blockbuster in antidepressant now before FDA

          AdobeCherylMeierhadwatchedclinicaltrialenrollmentannouncementsforyears—butalwaysforhersons’type1diab

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Welsh Carson private equity firm escapes from FTC antitrust case

          AjudgeruledthatWelshCarsonwon'thavetofaceantitrustallegationsaboutitsanesthesiologypractice.AdobeWel